Kaituo Pharma's announcement on the HKEX reveals that the company's China phase II clinical trial of GT20029 gel for acne, which was developed independently, has completed the first subject enrollment. GT20029 is the world's first topical PROTAC compound to enter phase II clinical trials.
开拓药业：GT20029凝胶治疗痤疮II期临床试验完成首例入组
Kaituo Pharmaceutical: The Phase II clinical trial of GT20029 gel for treating acne has completed the first enrollment.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.